

Title (en)

Compositions and methods for the treatment of infections and tumors

Title (de)

Zusammensetzungen und Verfahren zur Behandlung von Infektionen und Tumoren

Title (fr)

Compositions et procédés pour le traitement d'infections et de tumeurs

Publication

EP 2133365 A3 20100106 (EN)

Application

EP 09166886 A 20071226

Priority

- EP 07866029 A 20071226
- US 87751806 P 20061227

Abstract (en)

[origin: WO2008083174A2] PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.

IPC 8 full level

C07K 16/28 (2006.01); **A61K 39/12** (2006.01); **A61K 39/395** (2006.01); **A61P 31/14** (2006.01); **A61P 31/18** (2006.01); **A61P 31/20** (2006.01); **A61P 35/00** (2006.01); **A61K 39/00** (2006.01)

CPC (source: EP IL KR US)

A61K 31/20 (2013.01 - KR); **A61K 39/12** (2013.01 - EP IL KR US); **A61K 39/395** (2013.01 - EP IL KR US); **A61K 39/4611** (2023.05 - EP IL KR); **A61K 39/4636** (2023.05 - EP IL KR); **A61K 39/464838** (2023.05 - EP IL KR); **A61P 1/16** (2018.01 - EP); **A61P 29/00** (2018.01 - EP); **A61P 31/00** (2018.01 - EP); **A61P 31/06** (2018.01 - EP); **A61P 31/10** (2018.01 - EP); **A61P 31/12** (2018.01 - EP); **A61P 31/14** (2018.01 - EP); **A61P 31/16** (2018.01 - EP); **A61P 31/18** (2018.01 - EP); **A61P 31/20** (2018.01 - EP); **A61P 31/22** (2018.01 - EP); **A61P 33/00** (2018.01 - EP); **A61P 33/02** (2018.01 - EP); **A61P 33/06** (2018.01 - EP); **A61P 33/14** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 35/02** (2018.01 - EP); **A61P 37/04** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07K 16/2818** (2013.01 - EP IL US); **C07K 16/2827** (2013.01 - EP IL US); **A61K 2039/505** (2013.01 - EP IL US); **A61K 2039/507** (2013.01 - EP IL US); **A61K 2039/5158** (2013.01 - US); **A61K 2039/5256** (2013.01 - EP IL US); **A61K 2300/00** (2013.01 - IL); **C07K 2317/64** (2013.01 - EP US); **C12N 2710/24143** (2013.01 - EP IL US); **C12N 2740/16011** (2013.01 - EP IL US); **C12N 2760/10011** (2013.01 - EP IL US); **C12N 2760/10034** (2013.01 - EP IL US); **C12N 2770/24211** (2013.01 - EP IL US); **Y02A 50/30** (2018.01 - EP)

C-Set (source: EP US)

1. **A61K 39/12 + A61K 2300/00**
2. **A61K 39/395 + A61K 2300/00**

Citation (search report)

- [X] WO 2006133396 A2 20061214 - DANA FARBER CANCER INST INC [US], et al
- [X] STROME SCOTT E ET AL: "B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.", CANCER RESEARCH, vol. 63, no. 19, 1 October 2003 (2003-10-01), pages 6501 - 6505, XP002487684, ISSN: 0008-5472
- [X] CURIEL T J ET AL: "Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 9, no. 5, 1 May 2003 (2003-05-01), pages 562 - 567, XP002311470, ISSN: 1078-8956
- [X] CHRISTIAN BLANK ET AL: "Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 54, no. 4, 1 April 2005 (2005-04-01), pages 307 - 314, XP019333106, ISSN: 1432-0851
- [X] BLANK CHRISTIAN ET AL: "Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro", INTERNATIONAL JOURNAL OF CANCER, vol. 119, no. 2, July 2006 (2006-07-01), pages 317 - 327, XP002557386, ISSN: 0020-7136
- [Y] RILEY ET AL: "The road to recovery: translating PD-1 biology into clinical benefit", TRENDS IN IMMUNOLOGY, ELSEVIER, RAHWAY, NJ, US, vol. 28, no. 2, 22 December 2006 (2006-12-22), pages 48 - 50, XP005867493, ISSN: 1471-4906
- [Y] KNUTSON K L ET AL: "ADOPTIVE T-CELL THERAPY FOR THE TREATMENT OF SOLID TUMOURS", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 2, no. 1, 1 January 2002 (2002-01-01), pages 55 - 66, XP009043879, ISSN: 1471-2598
- [Y] YEE CASSIAN: "Adoptive T-cell therapy of cancer", HEMATOLOGY - ONCOLOGY CLINICS OF NORTH AMERICA, W.B. SAUNDERS, US, vol. 20, no. 3, 1 June 2006 (2006-06-01), pages 711 - 733, XP008093818, ISSN: 0889-8588
- [XP] WEBSTER W SCOTT ET AL: "Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 SEP 2007, vol. 179, no. 5, 1 September 2007 (2007-09-01), pages 2860 - 2869, XP002557388, ISSN: 0022-1767

Cited by

CN108299546A; CN107922503A; US11168144B2; US10513558B2; US9724390B2; US10232017B2; US11993653B2; US10465014B2; US11136413B2; US10323091B2; US10450373B2; US11345755B2; US10336824B2; US10669339B2; US11174316B2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2008083174 A2 20080710; WO 2008083174 A3 20081218; AU 2007339897 A1 20080710; AU 2007339897 B2 20130214; BR P10720724 A2 20140401; CA 2673870 A1 20080710; CA 2947292 A1 20080710; CA 2947292 C 20190723; CA 3045637 A1 20080710; CN 101663323 A 20100303; CN 103536915 A 20140129; CN 105056226 A 20151118; EP 2079760 A2 20090722; EP 2079760 B1 20160427; EP 2133365 A2 20091216; EP 2133365 A3 20100106; EP 2133365 B1 20170517; EP 3064220 A2 20160907; EP 3064220 A3 20161207; EP 3064220 B1 20200722; EP 3721903 A1 20201014; HK 1134679 A1 20100507; HU E030139 T2 20170428; IL 199517 A 20150831; IL 231077 A0 20140331; IL 240405 A0 20150924; IL 240405 A 20170529; IL 251637 A0 20170629; IL 251637 B 20191231; JP 2010514791 A 20100506; JP 2014210793 A 20141113; JP 2017002077 A 20170105; JP 2019163320 A 20190926; JP 5623747 B2 20141112; KR 101523391 B1 20150527; KR 20090094380 A 20090904; MX 2009006786 A 20091019; MX 351975 B 20171106; NZ 578650 A 20111222; NZ 594510 A 20120629; NZ 596237 A 20120727; NZ 600281 A 20130328; NZ 619576 A 20140725; NZ 626867 A 20140926;

NZ 629273 A 20150227; NZ 704295 A 20160624; NZ 720288 A 20200228; RU 2009128686 A 20110210; RU 2012153968 A 20140620;
RU 2478400 C2 20130410; RU 2540490 C2 20150210; SG 183663 A1 20120927; SI 2079760 T1 20161130; US 2010040614 A1 20100218;
US 2012251537 A1 20121004; US 2018155430 A1 20180607; US 2019031758 A1 20190131; US 2020223926 A1 20200716;
ZA 200904492 B 20220330

DOCDB simple family (application)

US 2007088851 W 20071226; AU 2007339897 A 20071226; BR PI0720724 A 20071226; CA 2673870 A 20071226; CA 2947292 A 20071226;
CA 3045637 A 20071226; CN 200780051749 A 20071226; CN 201210260742 A 20071226; CN 201510493422 A 20071226;
EP 07866029 A 20071226; EP 09166886 A 20071226; EP 16160525 A 20071226; EP 20174409 A 20071226; HK 10100656 A 20100121;
HU E07866029 A 20071226; IL 19951709 A 20090624; IL 23107714 A 20140220; IL 24040515 A 20150806; IL 25163717 A 20170406;
JP 2009544250 A 20071226; JP 2014136588 A 20140702; JP 2016186492 A 20160926; JP 2019104142 A 20190604;
KR 20097015114 A 20071226; MX 2009006786 A 20071226; MX 2012007788 A 20071226; NZ 57865007 A 20071226;
NZ 59451007 A 20071226; NZ 59623707 A 20071226; NZ 60028107 A 20071226; NZ 61957607 A 20071226; NZ 62686707 A 20071226;
NZ 62927307 A 20071226; NZ 70429507 A 20071226; NZ 72028807 A 20071226; RU 2009128686 A 20071226; RU 2012153968 A 20071226;
SG 2012056131 A 20071226; SI 200731811 A 20071226; US 201213436492 A 20120330; US 201715636510 A 20170628;
US 201815898108 A 20180215; US 201916550115 A 20190823; US 52130207 A 20071226; ZA 200904492 A 20090626